Novo Invests $2bn In Diabetes Franchise Growth
This article was originally published in Scrip
Danish diabetes drug maker Novo Nordisk launched a Phase IIIa clinical trial program for the oral version of its glucagon-like peptide-1 (GLP-1) analog semaglutide on 26 August and simultaneously revealed plans to invest $2bn in manufacturing to support the potential blockbuster diabetes drug.
You may also be interested in...
TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.